Outlook Therapeutics, Inc. — Director's Dealing 2018

Sep 25, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncobiologics, Inc. (ONS)
CIK: 0001649989
Period of Report: 2018-09-21

Reporting Person: THURMAN RANDY H (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-21	Stock Option (Right to Buy)	$0.9155	A	15000	Acquired	2028-09-21	Common Stock (15000)	Direct

Footnotes

F1: 100% of the shares underlying the option shall vest on September 21, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date.